Hydrochloric Acid → 1-(7-Amino-5-(3,8-diazabicyclo[3.2.1]octan-3-yl)-3-(6-phenylpyridin-3-yl)pyrazolo[1,5-a]pyrimidin-6-yl)ethanone
反応式
C[Si](C)(C)CCOC[N:7](COCC[Si](C)(C)C)[C:8]1[N:13]2[N:14]=[CH:15][C:16]([C:17]3[CH:18]=[N:19][C:20]([C:23]4[CH:28]=[CH:27][CH:26]=[CH:25][CH:24]=4)=[CH:21][CH:22]=3)=[C:12]2[N:11]=[C:10]([N:29]2[CH2:35][CH:34]3[N:36](C(OC(C)(C)C)=O)[CH:31]([CH2:32][CH2:33]3)[CH2:30]2)[C:9]=1[C:44]([O:46]CC)=[CH2:45].Cl>O>[NH2:7][C:8]1[N:13]2[N:14]=[CH:15][C:16]([C:17]3[CH:18]=[N:19][C:20]([C:23]4[CH:24]=[CH:25][CH:26]=[CH:27][CH:28]=4)=[CH:21][CH:22]=3)=[C:12]2[N:11]=[C:10]([N:29]2[CH2:35][CH:34]3[NH:36][CH:31]([CH2:32][CH2:33]3)[CH2:30]2)[C:9]=1[C:44](=[O:46])[CH3:45]参加物
4
反応物 2
生成物 1
試薬・触媒・溶媒 1
実験手順
The tert-butyl 3-(7-(bis((2-(trimethylsilyl)ethoxy)methyl)amino)-6-(1-ethoxyvinyl)-3-(6-phenylpyridin-3-yl)pyrazolo[1,5-a]pyrimidin-5-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (31 mg) was treated with 4N HCl in H2O (2 mL) and Dixoane (2 mL) until the disappearance of starting material in LCMS. Concentration afforded crude 1-(7-amino-5-(3,8-diazabicyclo[3.2.1]octan-3-yl)-3-(6-phenylpyridin-3-yl)pyrazolo[1,5-a]pyrimidin-6-yl)ethanone, which was used for next step without further purification, LCMS tR=1.08 Min (10 min run, UV254nm). Mass calculated for, M+H 440.2, observed LC/MS m/z 440.2 (M+H).
後処理
- concentrationConcentration
出典と根拠
- ORDレコード
- ord-2da378169e7446b5b9a510c2c0a69c57
- 出典データセット
- uspto-grants-2016_01
- 特許番号
- US09227971B2
反応ノート
読み込み中…